The Pfizer New Haven Clinical Research Unit is conducting a clinical trial of a study drug for respiratory syncytial virus (RSV). This study will look at the effects of multiple doses of the study drug compared to placebo and an additional medication in healthy adults.
RSV is a common and widespread cause of acute respiratory illness. Each year, it is estimated that more than 177,000 older adults are hospitalized and 14,000 of them die in the United States. Currently, there is no cure or vaccine for RSV, and therapeutics are limited. There is a great medical need to develop a safe and effective treatment to help patients who become ill with this virus.
Read more below about how you can get involved and help patients breathe easier.
Who may participate
Each clinical study has its own guidelines for who can participate, called eligibility criteria. However, only the research study staff can determine if you qualify to enroll in the study.
What to expect
All of the study procedures will be clearly explained to you during screening and can be viewed by downloading the informed consent form.
Interested in participating?
Complete and submit this form, and a Pfizer New Haven Clinical Research Unit (PCRU) representative will contact you. Please note: volunteers completing this form must be able to read and speak English at an 8th grade level.
You may also call 1-800-254-6398 and speak with a PCRU representative to learn more.
For Japanese language assistance only, please call 1-833-711-9984. We apologize, our representatives cannot take calls in languages other than English or Japanese at this time.
The personal data gathered here will be collected, processed, and maintained in a confidential manner. Your information will be stored in our research unit’s database. We may use this information to invite you to participate in current and future clinical studies at the PCRU. You will have full access to your records at the Pfizer New Haven Clinical Research Unit and the opportunity to correct them if necessary.